These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
548 related articles for article (PubMed ID: 35712757)
1. Wei Z; Shen Y; Zhou C; Cao Y; Deng H; Shen Z Bioengineered; 2022 May; 13(5):13784-13800. PubMed ID: 35712757 [TBL] [Abstract][Full Text] [Related]
2. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC. Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648 [TBL] [Abstract][Full Text] [Related]
3. An ion-channel-gene-based prediction model for head and neck squamous cell carcinoma: Prognostic assessment and treatment guidance. Han Y; Shi Y; Chen B; Wang J; Liu Y; Sheng S; Fu Z; Shen C; Wang X; Yin S; Li H Front Immunol; 2022; 13():961695. PubMed ID: 36389709 [TBL] [Abstract][Full Text] [Related]
4. Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584 [TBL] [Abstract][Full Text] [Related]
5. A novel Pyroptosis-related long non-coding RNA signature for predicting the prognosis and immune landscape of head and neck squamous cell carcinoma. Zhou C; Shen Y; Jin Y; Shen Z; Ye D; Shen Y; Deng H Cancer Med; 2022 Dec; 11(24):5097-5112. PubMed ID: 35567376 [TBL] [Abstract][Full Text] [Related]
6. Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma. Shi Y; Huang J; Hu Y; Shen Y BMC Bioinformatics; 2023 Jun; 24(1):269. PubMed ID: 37386359 [TBL] [Abstract][Full Text] [Related]
7. Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma. Huang J; Xu Z; Wang Z; Zhou C; Shen Y Curr Cancer Drug Targets; 2024; 24(8):804-819. PubMed ID: 38310463 [TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients. Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X Front Immunol; 2022; 13():1100417. PubMed ID: 36703967 [TBL] [Abstract][Full Text] [Related]
9. Lactate dehydrogenase B as a metabolism-related marker for immunotherapy in head and neck squamous cell carcinoma. Xu X; Pan X; Fan Z; Xia J; Ren X Cell Signal; 2024 Aug; 120():111200. PubMed ID: 38719019 [TBL] [Abstract][Full Text] [Related]
10. Multi-omic analysis and validation reveal ZBP1 as a potential prognostic and immunotherapy-related biomarker in head and neck squamous cell carcinoma. Li Y; Wang N; Yang G J Stomatol Oral Maxillofac Surg; 2024 Sep; 125(4S):101901. PubMed ID: 38688403 [TBL] [Abstract][Full Text] [Related]
11. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma. Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL Front Immunol; 2022; 13():969034. PubMed ID: 36466881 [TBL] [Abstract][Full Text] [Related]
12. AVPR2 is a potential prognostic biomarker and correlated with immune infiltration in head and neck squamous cell carcinoma. Mao L; Pan Z; Chen W; Hu W; Chen X; Dai H BMC Med Genomics; 2023 Mar; 16(1):67. PubMed ID: 36998036 [TBL] [Abstract][Full Text] [Related]
13. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer. Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791 [No Abstract] [Full Text] [Related]
14. Mast cell marker gene signature in head and neck squamous cell carcinoma. Cai Z; Tang B; Chen L; Lei W BMC Cancer; 2022 May; 22(1):577. PubMed ID: 35610596 [TBL] [Abstract][Full Text] [Related]
15. CELSR3 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment. Wu Z; Zhu Z; Wu W; Hu S; Cao J; Huang X; Xie Q; Deng C Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3143-3156. PubMed ID: 38507078 [TBL] [Abstract][Full Text] [Related]
16. Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature. Liu L; Liu Q Sci Rep; 2024 Apr; 14(1):9914. PubMed ID: 38688945 [TBL] [Abstract][Full Text] [Related]
17. SLA2 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment. Wu Z; You C; Zhu Z; Wu W; Cao J; Xie Q; Deng C; Huang X; Hu S Eur Arch Otorhinolaryngol; 2024 Jan; 281(1):427-440. PubMed ID: 37688682 [TBL] [Abstract][Full Text] [Related]
18. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status. Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma. Yao Y; Yan Z; Lian S; Wei L; Zhou C; Feng D; Zhang Y; Yang J; Li M; Chen Y J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32719094 [TBL] [Abstract][Full Text] [Related]